Voluntary Reporting on Suspected Drug Reactions Collected via Drug Companies in Japan : Companies' View
نویسندگان
چکیده
منابع مشابه
Doctors and drug companies.
When a great profession and the forces of capitalism interact, drama is likely to result. This has certainly been the case where the profession of medicine and the pharmaceutical industry are concerned. On display in the relationship between doctors and drug companies are the grandeur and weaknesses of the medical profession — its noble aspirations and its continuing inability to fulfill them. ...
متن کاملBias in Spontaneous Reporting of Adverse Drug Reactions in Japan
BACKGROUND Attitudes of healthcare professionals regarding spontaneous reporting of adverse drug reactions (ADRs) in Japan are not well known, and Japan's unique system of surveillance, called early post-marketing phase vigilance (EPPV), may affect these reporting attitudes. Our objectives were to describe potential effects of EPPV and to test whether ADR seriousness, prominence, and frequency ...
متن کاملReporting adverse drug reactions.
and are available from booksellers through the network of WHO sales agents. A list of these agents may be obtained by writing to the above address. (CIOMS) is a nongovernmental organization established jointly by the World Health Organization and UNESCO in 1949, with a mandate to collaborate with the United Nations and its specialized agencies. Its international membership, consisting of intern...
متن کاملOf doctor conventions and drug companies.
Pharmaceutical companies provide the majority of financial support for staging the American Academy of Family Physicians (AAFP) Annual Scientific Assembly. In return they are allowed to dominate the physical and mental environment. The assembly is opulent and entertaining, but undoubtedly much of the expense is passed to the health care consumer in the form of high-priced brand-name prescriptio...
متن کاملWhen Can Patients Sue Drug Companies?
Vol. 34 No. 5 • May 2009 • P&T® 243 (see the April issue of P&T, page 175). Ms. Levine sued and received a settlement from the clinic where the drug was administered. She also named Wyeth as a defendant, claiming that the drug’s label should have more clearly instructed clinicians against using an IV push injection. The label, which the FDA had approved, warned about inadvertent intra-arterial ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku
سال: 1997
ISSN: 1342-0445,1882-790X
DOI: 10.3820/jjpe1996.2.111